Medical Chemical Defense (Op Sys Dev)
Abstract
This project provides for the upgrade and modernization of fielded medical nerve agent treatment system that contribute to the layered medical defenses against chemical warfare agent threats facing U.S. Forces in the field. In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP portfolio. MC7 efforts in FY2022 progress to the Mitigate (MT7) portfolio. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts. The effort included in this project is: (1) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) **Progresses to MT7 in FY2023** The INATS CA program provides a centrally-acting anticholinergic agent to increase survivability and decrease morbidity after exposure to toxic nerve agent threats. Scopolamine was selected for development after an extensive analysis of alternatives and review of data by the Science and Technology community. Added to the currently fielded system, the INATS-CA program will improve overall medical outcomes and will be utilized as both a vial for use at definitive care and a stand-alone auto-injector for use in the field. In FY23 INATS CA continues studies on the FDA-approved Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP), a medical pre-treatment against nerve agent poisoning to upgrade its joint service utility and ensure its continued safety and efficacy.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2023
- Source ID
- MC7_0607384BP_7_0400_PB_2023
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (OP SYS DEV)
- Child Accomplishment: 1) INATS - CA
- Child Accomplishment: 2) INATS - CA
- Child Cost Item: 7137b79871326cfdae4bb755b12b82a1
- Child Cost Item: da377dd3d06fb7f308fb61da8909919f
- Child Cost Item: bfaf885806b1b12790ab282007bc634a
- Child Cost Item: a7731269f333c22e2ebd99b6b0fe4b14